Table 1. Based off cell-based screening assays, these two FDA-approved compounds were determined to be good candidates to be repurposed as a sclerostin small-molecule inhibitor (SMI) for bone regeneration.

MOA, mechanism of action.

Drug name	MOA	Current use	Dosing	Metabolism
Fluticasone (F)	Glucocorticoid receptor agonist	Topical anti-inflammatory	100–2000 µg/day	Hepatic
Valproic acid (VA1)	Unknown	Anti-epileptic drug, migraines	15–60 mg/kg/day	Hepatic